Resona Asset Management Co. Ltd. Acquires Shares of 121,486 DexCom, Inc. (NASDAQ:DXCM)

Resona Asset Management Co. Ltd. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 121,486 shares of the medical device company's stock, valued at approximately $9,494,000.

Other hedge funds have also added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new stake in DexCom in the 4th quarter valued at $25,000. Private Trust Co. NA grew its stake in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC lifted its position in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in DexCom in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Activity

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company's stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is currently owned by insiders.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday, March 21st. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup increased their price target on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Finally, Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $99.00.

DexCom Price Performance

Shares of NASDAQ DXCM traded down $1.32 during midday trading on Friday, hitting $65.98. 1,302,740 shares of the company's stock were exchanged, compared to its average volume of 4,166,337. The business's fifty day moving average price is $77.35 and its two-hundred day moving average price is $76.62. The company has a market cap of $25.87 billion, a price-to-earnings ratio of 46.15, a PEG ratio of 2.30 and a beta of 1.50. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $141.25.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.